QuintilesIMS Selected As Strategic Partner For Upcoming Fervent Product

Fervent Pharmaceuticals is happy to announce QuintilesIMS as its first strategic partner. QuintilesIMS will work closely with members of Fervent’s team as they work towards developing their groundbreaking FP-101 treatment for hot flashes and other vasomotor symptoms. QuintileIMS contributes their many years of CRO experience and deep history with women’s health products, as well as provide invaluable insights into the clinical development process.

QuintilesIMS is one of the world’s largest contract research organization. The company specializes in providing research, marketing, and a wide variety of other services for pharmaceutical firms looking to outsource portions of their operations. The services offered by Quintiles include performing clinical trials of new drugs, laboratory services, biostatistical analysis, and data management.

“QuintilesIMS offers everything that a company like ours has been looking for in a strategic partner,” Fervent CEO George Royster commented. “Their incredible depth of experience and expertise will be crucial as we continue developing FP-101 and prepare it for clinical trials. They’re a large company, but they’ve already demonstrated their ability to give Fervent the time and attention needed to make FP-101 a success and help relieve the suffering of women around the world dealing with hot flashes.”

FP-101’s development journey is progressing quickly, and Fervent will be announcing additional strategic partnerships shortly.